Research Summary · Cardiology

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

July 19, 2026

LDL-C reduction (ASCVD/high-risk)

56%

LDL-C reduction (HeFH)

59%

Trial population (total)

3,207

Primary endpoint

Percent change in LDL-C from baseline to Week 24

Approval date

July 17, 2026

Administration

Once-daily oral tablet

Clinical Perspective

This approval affects clinicians who treat adults with hypercholesterolemia, including those managing patients with heterozygous familial hypercholesterolemia, by adding an oral PCSK9 inhibitor to the therapeutic armamentarium ^[2]. The trial data support that once-daily oral enlicitide produces large, sustained LDL-C reductions (56% in the ASCVD/high-risk cohort and 59% in HeFH at Week 24) on top of maximally tolerated statin therapy ^[2]^[3]^[1]. Will Lipfendra’s LDL-C lowering translate into reductions in major adverse cardiovascular events comparable to injectable PCSK9 inhibitors in real-world practice and dedicated outcomes studies?

Dr. Kavya Sharma · Cardiology

The FDA approved Lipfendra (enlicitide) on July 17, 2026 as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) ^[2]. Approval was based on two randomized, double-blind, placebo-controlled phase 3 trials (CORALreef Lipids1 and CORALreef heFH) that showed mean LDL-C reductions of 56% and 59% at Week 24 versus placebo, respectively ^[1]^[2].

Clinical Context

PCSK9 inhibition has been a high-efficacy approach to lower LDL-C but, until this approval, available PCSK9 inhibitors required injection; Lipfendra is the first oral PCSK9 inhibitor approved by the FDA ^[2]. The pivotal development program enrolled adults with severe hypercholesterolemia on maximally tolerated statin therapy, including cohorts with established atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk and a dedicated HeFH cohort ^[2]^[3]. The trials measured percent change in LDL-C from baseline to Week 24 as the primary endpoint and reported sustained LDL-C lowering through 24–52 weeks in the phase 3 program ^[1]. The program also reported improvements in other lipid parameters, and the authors and FDA noted efficacy comparable to monoclonal antibody PCSK9 inhibitors in percentage LDL-C lowering ^[1]^[2].

Key Findings

The CORALreef Lipids1 trial showed enlicitide (Lipfendra) reduced LDL-C by 56% versus placebo at Week 24 in adults with ASCVD or at high risk for ASCVD who were receiving maximally tolerated statin therapy; baseline LDL-C in this cohort averaged 96 mg/dL ^[2]^[3].
Clinicians should consult current prescribing information for full dosing guidance.
The CORALreef heFH trial showed enlicitide (Lipfendra) reduced LDL-C by 59% versus placebo at Week 24 in adults with heterozygous familial hypercholesterolemia (HeFH) receiving maximally tolerated statin therapy; baseline LDL-C in this cohort averaged 119 mg/dL ^[2]^[3].
Reductions in LDL-C were reported as sustained through 24–52 weeks across the phase 3 program and were accompanied by improvements in other lipid parameters as reported in the phase 3 publication ^[1].
The combined randomized, double-blind, placebo-controlled program included a total of 3,207 adults with severe hypercholesterolemia across the two trials, and the primary endpoint for both trials was percent change in LDL-C from baseline to Week 24 versus placebo ^[2]^[3].
The published phase 3 report and the FDA summary characterized enlicitide’s LDL-C lowering as similar in magnitude to monoclonal antibody PCSK9 inhibitors in the trial populations studied ^[1]^[2].

Safety & Tolerability

Safety outcomes were reported as comparable to placebo in the phase 3 program ^[1].
Diarrhea was reported at higher frequency with Lipfendra than placebo in the HeFH trial ^[3].
Dizziness was reported at higher frequency with Lipfendra than placebo in the HeFH trial ^[3].

Study Design

The enlicitide development program comprised two randomized, double-blind, placebo-controlled phase 3 trials named CORALreef Lipids1 and CORALreef heFH ^[1]^[2]. The two trials together enrolled 3,207 adults with severe hypercholesterolemia who were receiving maximally tolerated statin therapy; CORALreef Lipids1 enrolled adults with established ASCVD or at high risk for ASCVD (mean baseline LDL-C 96 mg/dL) and CORALreef heFH enrolled adults with heterozygous familial hypercholesterolemia (mean baseline LDL-C 119 mg/dL) ^[2]^[3]. Clinicians should consult current prescribing information for full dosing guidance. The primary endpoint in both trials was percent change in LDL-C from baseline to Week 24 compared with placebo; the trials were double-blind and placebo-controlled ^[2]^[3]. Reductions in LDL-C were sustained through 24–52 weeks in the phase 3 program according to the published report ^[1]. Details on randomization ratio, statistical models, prespecified secondary endpoints beyond other lipid parameters, and certain procedural details were not available in the provided source excerpts.

FAQ

Q1 What is enlicitide (Lipfendra) approved for?

Lipfendra (enlicitide) is approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including adults with heterozygous familial hypercholesterolemia (HeFH). The FDA approval was announced July 17, 2026 and was supported by two randomized, double-blind, placebo-controlled phase 3 trials showing large LDL-C reductions at Week 24.

Q2 How does enlicitide work?

Enlicitide is an oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting PCSK9, the drug reduces circulating LDL-C levels; Lipfendra is the first oral therapy approved to inhibit PCSK9 according to the FDA announcement and the phase 3 publication.

Q3 What is the recommended dose of Lipfendra?

Dosing information was not available in the provided source excerpts.

Q4 What are the most common side effects?

Across the phase 3 program overall, adverse reaction frequency was reported as similar between Lipfendra and placebo in the ASCVD/high-risk trial. In the HeFH trial, the adverse reactions reported at higher frequency with Lipfendra than placebo included diarrhea and dizziness. Safety outcomes in the published phase 3 report were characterized as comparable to placebo.

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Cardiology in your inbox.

Related Clinical Updates

Evolocumab Cuts LDL 63%; Alirocumab and Inclisiran: Data Guide

STRIDE: Semaglutide Increases Walking Distance 1.13-Fold in PAD with T2D

FDA Approves Baxdrostat for Resistant Hypertension: 9.8 mmHg SBP

Verified HCP Portal